You are in: eMedicine Specialties > Emergency Medicine > OBSTETRICS AND GYNECOLOGY Pregnancy, Postpartum InfectionsArticle Last Updated: Aug 8, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Elicia S Kennedy, MD, Clinical Assistant Professor, Department of Emergency Medicine, University of Arkansas for Medical Sciences Elicia S Kennedy is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine Editors: Assaad J Sayah, MD, Chief, Department of Emergency Medicine, Cambridge Health Alliance; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Mark Zwanger, MD, MBA, Assistant Professor, Department of Emergency Medicine, Thomas Jefferson University; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Pamela L Dyne, MD, Associate Professor, Program Director, Department of Medicine, Division of Emergency Medicine, University of California at Los Angeles School of Medicine Author and Editor Disclosure Synonyms and related keywords: endometritis, puerperal infection, postsurgical wound infections, perineal cellulitis, mastitis, respiratory complications from anesthesia, retained products of conception, urinary tract infections, UTI, septic pelvic phlebitis, mastitis, pyelonephritis, genital tract infections, thrombosis, perineal cellulitis, episiotomy, Bacteroides, Clostridium, Escherichia coli, E coli, Staphylococcus aureus, S aureus, Klebsiella, Proteus, Enterobacter INTRODUCTIONBackgroundEmergency physicians are increasingly concerned about postpartum patients who come to the ED with a fever or evidence of infection. The number of cases of infection can be expected to increase because of the earlier discharge of postpartum patients from the hospital. Any infection following delivery is classified as postpartum or puerperal infection. PathophysiologyEndometritis is the most common source of postpartum infection. Other sources of postpartum infections include (1) postsurgical wound infections, (2) perineal cellulitis, (3) mastitis, (4) respiratory complications from anesthesia, (5) retained products of conception, (6) urinary tract infections (UTIs), and (7) septic pelvic phlebitis. FrequencyUnited StatesOverall, postpartum infection is estimated to occur in 1-8% of all deliveries. Mortality/MorbidityIn most reviews, maternal death rates associated with infection range from 4-8%, or approximately 0.6 maternal deaths per 100,000 live births. CLINICALHistoryThe history and course of the delivery is important in the evaluation of postpartum patients.
PhysicalFocus the physical examination on identifying the source of fever and infection. A complete physical examination, including pelvic and breast examinations, is necessary. Findings may include the following:
CausesCauses and risk factors may include the following:
DIFFERENTIALSCellulitis Pelvic Inflammatory Disease Urinary Tract Infection, Female Vaginitis
|
| Drug Name | Cefoxitin (Mefoxin) |
|---|---|
| Description | Second-generation cephalosporin indicated for gram-positive coccal and gram-negative rod infections. Infections caused by cephalosporin-resistant or penicillin-resistant gram-negative bacteria may respond to cefoxitin. Must be used with clindamycin or doxycycline and an aminoglycoside for the treatment of endometritis, for which it is a DOC. Particularly important in early postpartum (first 48 h) infections. |
| Adult Dose | 2 g IV q6-8h |
| Pediatric Dose | 80-160 mg/kg/d IV divided q4-6h; higher doses for more severe infections; not to exceed 12 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effects; concurrent use with aminoglycosides or furosemide may increase nephrotoxicity (closely monitor renal function) |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged use or repeated treatment; caution in previously diagnosed colitis |
| Drug Name | Doxycycline (Bio-Tab, Doryx) |
|---|---|
| Description | Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Must be used with other drugs for endometritis. Used often for outpatient therapy for late postpartum (48 h to 6 wk after delivery) treatment. |
| Adult Dose | 100 mg PO/IV q12h for 14 d |
| Pediatric Dose | <8 years: Contraindicated >8 years: 2-5 mg/kg/d PO/IV qd or divided bid |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last half of pregnancy through age 8 y) can permanently discolor teeth; Fanconi-like syndrome may occur with outdated tetracyclines |
| Drug Name | Gentamicin (Garamycin) |
|---|---|
| Description | Aminoglycoside antibiotic used for gram-negative bacterial coverage. Commonly used with an agent against gram-positive organisms in treatment of endometritis. Not the DOC. Consider if penicillins or other less toxic drugs are contraindicated, when clinically indicated, and in mixed infections caused by susceptible staphylococci and gram-negative organisms. Dosing regimens are numerous and adjusted on the basis of CrCl and changes in volume of distribution. Gentamicin may be given IV/IM. |
| Adult Dose | 1 mg/kg IV q12h |
| Pediatric Dose | <5 years: Not established >5 years: 1.5-2.5 mg/kg/dose IV/IM q8h or 6-7.5 mg/kg/d IV/IM divided q8h; not to exceed 300 mg/d |
| Contraindications | Documented hypersensitivity; non–dialysis-dependent renal insufficiency |
| Interactions | Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents thus prolong respiratory depression; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus |
| Precautions | Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (patients not undergoing dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at the bacterial ribosome where it binds preferentially to the 50S ribosomal subunit, causing bacterial growth inhibition. Must be used with other drugs in the treatment of endometritis. Second drug of choice, after dicloxacillin, in postpartum mastitis. |
| Adult Dose | 450-900 mg IV/IM q8h or 300 mg PO q6h |
| Pediatric Dose | 20-40 mg/kg/d IV/IM divided tid/qid or 8-20 mg/kg/d PO as hydrochloride, with 8-25 mg/kg/d as palmitate divided tid/qid |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade, induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
| Drug Name | Dicloxacillin (Dycill, Dynapen, Pathocil) |
|---|---|
| Description | Bactericidal antibiotic that inhibits cell wall synthesis. Used in treatment of infections caused by penicillinase-producing staphylococci. Primary drug of choice used for postpartum mastitis to cover S aureus. |
| Adult Dose | 500 mg PO q6h |
| Pediatric Dose | <40 kg: 12.5 mg/kg/d PO q6h >40 kg: 125 mg PO q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Decreases efficacy of oral contraceptives; increases effects of anticoagulants; probenecid and disulfiram may increase penicillin levels; concurrent tetracyclines may decrease effectiveness |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Monitor PT in patients taking anticoagulant medications; toxicity may increase in renal impairment |
| Drug Name | Metronidazole (Flagyl) |
|---|---|
| Description | Used with heparin and third-generation parenteral cephalosporin in the treatment of septic pelvic vein thrombophlebitis to cover streptococci and Bacteroides and Enterobacteriaceae species. |
| Adult Dose | 500 mg PO/IV q6h |
| Pediatric Dose | 15-30 mg/kg/d PO/IV divided bid/tid for 7 d |
| Contraindications | Documented hypersensitivity |
| Interactions | May increase toxicity of anticoagulants, lithium, and phenytoin; cimetidine may increase toxicity; disulfiram reaction may occur with orally ingested ethanol |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in hepatic disease; monitor for seizures and development of peripheral neuropathy |
| Drug Name | Cephalexin (Keflex) |
|---|---|
| Description | First-generation cephalosporin used to cover S aureus in mastitis. Encourage the mother to continue breastfeeding to shorten duration of symptoms. Another DOC for postpartum mastitis. |
| Adult Dose | 500 mg PO qid for 10-14 d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aminoglycosides increase nephrotoxic potential |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal impairment |
Pregnancy, Postpartum Infections excerpt
Article Last Updated: Aug 8, 2007